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Abstract: The importance of safer approaches for gene therapy has been underscored by a series of severe adverse events 
(SAEs) observed in patients involved in clinical trials for Severe Combined Immune Deficiency Disease (SCID) and 
Chromic Granulomatous Disease (CGD). While a new generation of viral vectors is in the process of replacing the classi-
cal gamma-retrovirus–based approach, a number of strategies have emerged based on non-viral vectorization and/or tar-
geted insertion aimed at achieving safer gene transfer. Currently, these methods display lower efficacies than viral trans-
duction although many of them can yield more than 1% engineered cells in vitro. Nuclease-based approaches, wherein an 
endonuclease is used to trigger site-specific genome editing, can significantly increase the percentage of targeted cells. 
These methods therefore provide a real alternative to classical gene transfer as well as gene editing. However, the first en-
donuclease to be in clinic today is not used for gene transfer, but to inactivate a gene (CCR5) required for HIV infection. 
Here, we review these alternative approaches, with a special emphasis on meganucleases, a family of naturally occurring 
rare-cutting endonucleases, and speculate on their current and future potential. 
Keywords: Homing endonuclease, Zinc-finger nuclease, Recombinase, Transposons, gene transfer, protein engineering, viral 
vector. 
INTRODUCTION TO TARGETED APPROACHES 
Different Strategies for Safer Gene Therapy 
  At the turn of the last millennium, the successful treat-
ment of several X-SCID patients was a major milestone in 
the field of gene therapy [1, 2]. However, the importance of 
safer approaches has been emphasized by a series of severe 
adverse events (SAEs); e.g. the appearance of leukemia in X-
SCID treated patients [3-5] and of myelodysplasia in a clini-
cal trial for Chronic Granulomatous Disease (CGD) [6]. 
These SAEs were all associated with the integration of the 
transgene next to a proto-oncogene, and continued efforts 
have been devoted to the development of new, safer vectors. 
One such approach involves self-inactivating (SIN) gamma-
retrovirus and lentivirus-based vectors, which when inte-
grated lack enhancer and promoter sequences from the LTR 
[6-13]. These new vectors should decrease or alleviate the 
risks of proto-oncogene activation by insertional mutagene-
sis [14]. Meanwhile, these same SAEs fostered a growing 
interest for alternative strategies, which we will refer to as 
“targeted approaches” that consist of replacing random inte-
gration of therapeutic transgenes by targeted insertion or 
even correction of the deleterious mutation. Results are be-
ginning to accumulate for clinical trials using new viral vec-
tors [8, 15], and the first clinical trial using a targeted ap-
proach has been initiated [16]. Although additional time will 
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be necessary to evaluate more precisely the potentials and 
limits of each method, targeted approaches remain today, at 
least conceptually, more attractive than classical gene trans-
fer. 
Targeted Approaches: A Prosperous Methodology 
  Homologous gene targeting, first described in yeast by 
the laboratories of Gerald Fink [17], Jack Szostak [18-20] 
and, in its ultimate design, by Rodney Rothstein [21], was 
one of the first methods for rational genome engineering. 
This technique, successfully transferred to mammalian cells 
by the laboratories of Mario Capecchi [22-24] and Oliver 
Smithies [25-27], remains to this day a standard for the gen-
eration of engineered cells or knock-out mice [28]. An inher-
ently low efficiency has nevertheless prevented it from being 
used as a routine protocol in most cell types and organisms. 
As homologous gene targeting can typically be observed in 
only 10
-6 to 10
-9 of treated mammalian cells [29], such fre-
quencies did not obviate its use for gene and cell therapy. To 
address these issues, an extensive assortment of rational ap-
proaches has been proposed with the intent of achieving 
greater than 1% targeted modifications. The proven benefit 
of these emerging approaches lies in their ability to engineer 
the genome of a variety of cell types (including human stem 
cells). Nevertheless, researchers have invariably tried to as-
sess their potential for therapeutic applications. In the thera-
peutic field, the replacement of classical gene transfer (re-
sulting in random integration into the genome) with targeted 
gene insertion, or even targeted correction, has become a 12    Current Gene Therapy, 2011, Vol. 11, No. 1  Silva et al. 
commonly accepted potential solution and thus the goal of 
many laboratories. 
Targeted Approaches Based on Recombinases 
  Several targeting strategies rely on site-specific recombi-
nation processes mediated by recombinases or transposases. 
Such methods have an inherent advantage since these pro-
teins catalyze all the integration steps in a practically 
autonomous manner (e.g. transposases may require host fac-
tors). Their activity thus does not depend on the homologous 
recombination machinery. Homologous recombination is a 
complex maintenance system, and many studies argue that it 
is essentially active in the late S and G2 phases of the cell 
cycle [30-37]. As a consequence, the efficacy of recom-
binase or transposase-mediated integration should be rela-
tively cell-type independent, whereas methods based on ho-
mologous gene targeting would be very inefficient in post-
mitotic or quiescent cells. 
  The use of the Streptomyces phage C31 integrase to 
incorporate transgenes into the genome of mammalian cells 
provides an early example of a site-specific recombination 
approach. The C31 integrase is a serine recombinase that 
catalyzes the insertion of the phage genome into the bacterial 
genome via recombination between the phage attachment 
site (attP) and the bacterial attachment site (attB) [38, 39]. 
However, as pseudo integration sites can be found in mam-
malian cells, it was also possible to induce significant inte-
grase-mediated insertion in specific loci in mammalian 
chromosomes [40]. In subsequent experiments, this technol-
ogy was used to insert transgenes not only in a series of im-
mortalized cell lines but also primary cells [41-44], including 
human embryonic stem (hES) cells [41, 45]. The system 
proved robust enough for in vivo use, wherein co-injection of 
a C31 integrase expression cassette with a plasmid carry-
ing an attB site resulted in high frequencies of integration 
coupled with stable transgene expression in various tissues, 
such as mouse muscles [46, 47], rabbit joints [48], rat retina 
[49] and mouse liver [50, 51]. Using hydrodynamic injec-
tion, Olivares and colleagues observed integration in liver 
tissue at two major sites, one of which had detectable incor-
poration of a Factor IX transgene in 0.6 to 3.6% of total he-
patocytes [51]. This strategy is limited, however, by an in-
ability to choose the integration site. Whereas the most fa-
vored unique landing sequence occurred at chromosome 
19q13.31, circa one hundred other integration sites have 
been identified [52]. Recently, mutated derivates of C31 
with enhanced efficiency and specificity have been reported 
[53], offering great promise for success in the near term. 
  The Cre and FLP tyrosine recombinases have also been 
envisioned as reagents to mediate targeted insertions. These 
proteins have been widely used in genome engineering ex-
periments, albeit always to recombine transgenes carrying 
their respective target sequences. To this end, several at-
tempts have been made to redesign recombinase site-
specificity [54-57], the most remarkable involving a modi-
fied recombinase able to recognize sequences from the HIV1 
virus and used to excise a provirus from the human genome 
[54]. Whereas these studies were based on the redesign of 
the recombinase substrate specificity, an alternative strategy 
was used by other groups who fused the catalytic domain of 
the Tn3 resolvase or the Gin recombinase to a Zinc-finger-
based DNA-binding domain [58-60]. However, in these ini-
tial proof-of-concept designs the recombinase catalytic do-
main was still contributing to target preference. Using addi-
tional engineering steps, Gersbach and colleagues could sup-
press the target preference of the Gin moiety, thus producing 
a chimeric recombinase having essentially the selectivity of 
the chosen Zinc-finger DNA-binding domain [61]. 
Targeted Approaches Based on Transposons 
  The stable introduction of therapeutic transgenes into 
human cells can be accomplished by transposon-mediated 
gene transfer and has been proposed as an alternative to vi-
ral-mediated gene delivery [62-64]. As transposases can effi-
ciently catalyze gene transfer, transposition has long been 
used in Drosophila [65] to create transgenics. They have also 
widely been used in other organisms such as plants, fish, 
bacteria and others [66-68] in mutagenesis experiments. The 
inability of transposons to introduce a cargo of genetic mate-
rial into a cell in an autonomous manner is both an advantage 
and a drawback: unlike viruses they do not present risks of 
lateral transfer yet one needs to use them in association with 
a vector to introduce them into the cell. Several transposons 
have nonetheless been used in gene transfer experiments in 
vertebrate cells. The most advanced system is perhaps that 
derived from the Sleeping Beauty (SB) transposon, an an-
cient mobile genetic element in fish that could be modified 
to sustain elevated levels of activity in mammalian cells, 
with up to 5-10% integration [69, 70]. In similar experi-
ments, transposons based on the Piggy Back system were 
used to make induced pluripotent stem (iPS) cells [71, 72]. 
Importantly, the efficacy of transposase-mediated gene inser-
tion can be extremely high, and as a consequence high rates 
of gene transfer can be observed even with a suboptimal vec-
torization method. For example, the association of electropo-
ration methods and of the SB100X enhanced transposase 
results in an efficacy of gene insertion of up to 50% in 
CD34+ blood cells [70]. Transposons remain non-targeted 
gene transfer vehicles, and as such several attempts have 
been made to endow them with sequence specificity by fu-
sion with a DNA binding domain. Initial attempts with the 
SB transposon resulted in an enrichment for targeted integra-
tion in human cells [73]. More recently, the ISY100 transpo-
sase from a cyanobacteria transposon was fused with a Zinc-
finger DNA binding domain (Zif268) and used to efficiently 
target a specific site in E. coli.[74]. While promising as a 
proof-of-concept, the activity of this transposon in eukary-
otic cells is unknown. In terms of production, one of the ma-
jor drawbacks of viral vectors is the need for a tedious manu-
facturing process, a difficulty compounded in the case of 
therapeutic applications where Good Manufacturing Practice 
(GMP) is compulsory. The ability to achieve similar effica-
cies while circumventing these issues is a significant plus for 
transposon-based approaches. A clinical trial using SB-
mediated transfer of a chimeric antibody receptor (CAR) for 
the treatment of leukemia has recently been approved [75, 
76]. 
Targeted Approaches based on Homologous Recombina-
tion 
  In parallel to the development of methods based on site-
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hancing the efficacy of homologous gene targeting. Two 
major disciplines have become apparent: (i) methods that we 
will call “matrix optimization”, essentially consisting of 
modifying the targeting vector structure to achieve maximal 
efficacy, and; (ii) methods involving additional effectors to 
stimulate homologous recombination (HR), generally se-
quence-specific endonucleases. The field of matrix optimiza-
tion has covered a wide range of techniques, with varying 
degrees of success. For example, attempts to replace the 
DNA repair matrices used in classical gene targeting ex-
periments by chimeric DNA-RNA modified oligonucleo-
tides, including various modifications and/or specific secon-
dary structures, were initially seen as promising yet eventu-
ally proved inefficient in many experiments [77]. 
  Another type of optimization, Small Fragment Homolo-
gous Replacement (SFHR), relies on information exchange 
between short DNA fragments homologous to the targeted 
sequence and the endogenous locus [78]. The small size of 
the DNA fragment limits this approach to gene correction 
and does not allow for gene insertion or gene replacement 
experiments. All the same, SFHR was successfully applied 
to correct various mutations associated with monogenetic 
disorders. Very different frequencies have been reported, and 
a number of publications report correction of the human 
HPRT, CFTR, HBB and DMD genes in cell lines and pri-
mary cells, with frequencies in the range of 1% or even 10% 
of transfected cells [78-80]. A recent report describes correc-
tion of the CFTR gene in up to 60% of mouse ES cells [81]. 
  The use of Adeno-Associated Virus (AAV) as vectors for 
the repair matrix provides another way to increase HGT 
rates. Homologous gene targeting between an AAV vector 
and a chromosomal sequence can occur at frequencies in the 
range of 0.1-1.4 % in a variety of cell lines [82-84]. AAV-
mediated gene inactivation was also used to disrupt the 
COL1A1 and COL1A2 genes in human mesenchymal stem 
cells (MSCs) [85, 86] with an efficacy of 0.06-0.23% per 
treated cell for COL1A1. In addition, AAV-mediated gene 
targeting has been used to correct a LacZ marker at a fre-
quency of 0.1% in vivo in a mouse model [87]. Research 
continues towards optimized matrices, although as noted in 
the next section the use of effectors to stimulate HR is be-
coming more widespread. 
  Since the first reports of using the I-SceI meganuclease in 
mammalian cells, the practice of stimulating HR via nucle-
ases has become standard in many fields [88, 89]. I-SceI 
itself has been applied to numerous experimental designs in a 
variety of cell types and organisms (see below, “Use of me-
ganucleases for genome engineering”). In addition to natural 
endonucleases, other sequence specific nucleases have been 
investigated. Endonucleases for genome engineering have 
been classified into three groups by Pingoud and Silva [90]: 
chemical nucleases, ZFNs and meganucleases. This classifi-
cation should be updated given the recent emergence of a 
fourth category, the TALE nucleases (see below). 
  Chemical endonuclease are synthetic endonucleases re-
sulting from the fusion of DNA-reactive agents to a DNA-
binding polymer, such as triplex-forming oligonucleotides 
(TFO) and can in theory provide a straightforward solution 
(for review see [91]). Because the sequence specificity of 
such polymers can be designed a priori, it eliminates the 
extensive screening process usually necessary for the identi-
fication of a new peptidic DNA-binder. A variety of active 
domains such as a topoisomerase inhibitor (camptothecin) 
[92], psoralen [93], bypiridine [94], or a restriction enzyme 
[95] in fusion with TFO have been described as potential 
sequence-specific tools for genome engineering. While in 
principle promising, intracellular delivery, efficiency of en-
dogenous gene modifications as well as safety issues still 
need to be addressed for consideration in therapeutic applica-
tions. 
  To alleviate the delivery and safety issues associated with 
chemically-derived nucleases, attempts have been made to 
engineer protein endonucleases with programmable 
specificities. Among the most prevalent contenders are the 
Zinc-finger nucleases (ZFN), generated by fusing Zinc-
finger-based DNA binding domains to an independent cata-
lytic domain via a flexible linker [96-98]. The archetypal 
ZFNs are based on the catalytic domain of the Type IIS re-
striction enzyme FokI and have been successfully used to 
induce gene correction, gene insertion, and gene deletion. 
These studies have been reviewed by others [88, 99-102] and 
will not be described in detail. In summary, several groups 
have reported targeted HR events occurring at frequencies 
greater than 1% (and up to 50%) in immortalized human cell 
lines as well as primary cells including ES cells [103-109]. 
However, low efficacies have been reported in human ES, 
iPS [108] and hematopoietic stem cells (HSCs) [103]. Zinc 
Finger-based DNA binding domains are made of strings of 3 
or 4 individual Zinc Fingers, each recognizing a DNA triplet 
[110]. In theory, one of the major advantages of ZFNs is that 
they are easy to design, using combinatorial assembly of 
preexisting Zinc Fingers with known recognition patterns 
[111-113]. However, close examination of high resolution 
structures shows that there are actually cross-talks between 
units [114], and several methods have been used to assemble 
ZF proteins by choosing individual Zinc Fingers in a context 
dependant manner [106, 115-117] to achieve better success 
rates and reagents of better quality. 
  Recently, a new class of chimeric nucleases using a FokI 
catalytic domain have been described [118, 119]. The DNA 
binding domain of these nucleases is derived from Transcrip-
tion Activator Like Effectors (TALE), a family of proteins 
used in the infection process by plant pathogens of the Xan-
thomonas genus. In these DNA binding domains, sequence 
specificity is driven by a series of 33-35 amino acids repeats, 
differing essentially by two positions [120, 121]. In the DNA 
target, each base pair is contacted by a single repeat, the 
specificity resulting from the two variant amino acid of the 
repeat. The apparent modularity of these DNA binding do-
mains has been confirmed to a certain extent by modular 
assembly of designed TALE-derived protein with new 
specificities [120, 121]. However, one cannot yet rule out a 
certain level of context dependence of individual repeat/base 
recognition patterns, as was observed for Zinc Finger pro-
teins (see above). TALE-nucleases have been shown to be 
active in a cell-based assay in yeast [118, 119], and their 
exact level of engineerability, activity and specificity re-
mains to be explored. Nevertheless, the emergence of this 
promising new family of endonucleases highlights the fact 
that the list of reagents continues to grow. The FokI effector 
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ing domain, and the creation of functional I-SceI::FokI fu-
sions [122] illustrates this potential diversity. 
  While ZFNs have shown considerable promise, there has 
been a continued interest in the natural meganucleases given 
the extensive use of I-SceI by a large community of scien-
tists. Indeed, I-SceI has been used since the early nineties for 
genome engineering experiments and remains today the ref-
erence (“gold standard”) in the field with regard to activity 
and specificity. As the meganuclease family of which I-SceI 
is a member includes hundreds of other natural proteins, a 
special section has been included below (see “The Meganu-
clease Family”). 
Targeted Approaches based on Non-Homologous End-
Joining 
  In addition to the HR pathway for repairing double-
strand breaks (DSBs) in DNA, an error-prone DNA repair 
mechanism called non-homologous end joining (NHEJ) has 
been identified [123]. NHEJ seems to comprise at least two 
different components: (i) a pathway that consists mostly in 
the direct re-joining of DSB ends, and which depends on the 
XRCC4, Lig4 and Ku proteins, and; (ii) an alternative NHEJ 
pathway, which does not depend on XRCC4, Lig4 and Ku, 
and is especially error-prone, resulting mostly in deletions, 
with the junctions occurring between micro-homologies 
[124-129]. 
  For DSBs induced by biological reagents, e.g. meganu-
cleases and ZFNs, which cleave DNA by hydrolysis of two 
phosphodiester bonds, the DNA can be rejoined in a seam-
less manner by simple re-ligation of the cohesive ends. Al-
ternatively, deleterious insertions or deletions (indels) of 
various sizes can occur at the breaks, eventually resulting in 
gene inactivation [16, 106, 111, 130-135]. The nature of this 
process, which does not rely on site-specific or homologous 
recombination, gives rise to a third targeted approach based 
on endonuclease-induced mutagenesis. This approach, as 
well as the related applications, may be simpler than those 
based on homologous recombination in that (a) one does not 
need to introduce a repair matrix, and; (b) efficacy will be 
less cell-type dependant (in contrast to HR, NHEJ is proba-
bly active throughout the cell cycle [35]). 
  Targeted mutagenesis based on NEHJ has been used to 
trigger inactivation of single or even multiple genes in im-
mortalized cell lines [136, 137] . In addition, this method 
opens new perspectives for organisms in which the classical 
HR-based gene knock-out methods have proven inefficient, 
or at least difficult to establish, such as rat [138-140], fish 
[131] and plants [106, 134, 141, 142]. Interestingly, the first 
clinical trial launched with ZFNs relies on ZFN-mediated 
mutagenesis of the human CCR5 gene [16] in order to block 
HIV1 entry into T-cells in AIDS patients (see below, “Tar-
geted mutagenesis of human genes”). 
THE MEGANUCLEASE FAMILY OF ENDONUCLE-
ASES: PROPERTIES AND USE 
  As outlined previously, endonucleases for genome engi-
neering can be classified into four groups: chemical nucle-
ases, ZFNs, meganucleases [90], and now, TALE-nucleases 
[118, 119]. This section focuses on meganucleases, which 
have been used for more than 15 years to induce gene target-
ing. Recent advances in re-engineering meganuclease speci-
ficity have further enhanced their scope of application. The 
scores of publications and contributions to scientific meet-
ings related to meganucleases reveal a significant evolution 
in adoption and applicability, with a growing community 
finding an interest in the exceptional properties of these pro-
teins. 
The Meganuclease Family 
  Meganucleases, also called homing endonucleases, can 
be divided into five families based on sequence and structure 
motifs: LAGLIDADG, GIY-YIG, HNH, His-Cys box and 
PD-(D/E)XK [143, 144]. The most well studied family is 
that of the LAGLIDADG proteins, which have been found in 
all kingdoms of life, generally encoded within introns or 
inteins although freestanding members also exist. To date, a 
purposeful role within the host has not been identified for 
these proteins and they tend to be classified as “selfish ge-
netic elements”. With few exceptions, LAGLIDADG pro-
teins exhibit one of two primary activities: (a) they function 
as RNA maturases involved in facilitating the splicing of 
their own intron, or; (b) they function as highly specific en-
donucleases capable of recognizing and cleaving the exon-
exon junction sequence wherein their intron resides, thus 
giving rise to the moniker “homing endonuclease”. It has 
been hypothesized that homing endonucleases have a so-
called “life-cycle” [145] as illustrated in Fig. (1) (i) first, 
they start out as invasive endonucleases capable of mobiliz-
ing their coding sequence; (ii) upon “invasion”, they acquire 
a concomitant RNA maturase activity to help ensure proper 
splicing of their intron; (iii) over time, the “invasive” nucle-
ase activity is lost, leaving only the RNA maturase function, 
and (iv) finally, upon losing the maturase activity, propaga-
tion of the intron becomes unviable and the intron is lost. It 
is thus inferred that the functionality of a given LAGLI-
DADG protein (endonuclease, maturase, or both) represents 
a snapshot into the current state of its lifecycle. 
Structure of LAGLIDADG Endonucleases 
  A considerable body of both biochemical and genetic 
work had established that LAGLIDADG homing endonucle-
ases could be used as molecular tools. It had long been 
known that the defining sequence motif, LAGLIDADG, rep-
resented an essential element for enzymatic activity. Some 
proteins contained only one such motif, while others con-
tained two; in both cases the motifs were followed by ~75-
200 amino acid residues having little to no sequence similar-
ity with other family members. In 1997, two groups shed 
light on the organization of LAGLIDADG proteins with the 
structure of both a single-motif protein (I-CreI) [146] and an 
intein-encoded double-motif protein (PI-SceI) [147]. In both 
cases the endonuclease domain adopted a similar  
fold, with the LAGLIDADG motif comprising the terminal 
region of the first helix and not only contributing to a bipar-
tite catalytic center but also forming the core subunit/subunit 
interaction. Two such / domains assemble to form the 
functional protein, with the -strands in each creating a sad-
dle-shaped DNA binding region. That two such subunits 
were needed for function could be definitively established, as 
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tecture similar to that of the double-motif endonuclease do-
main of PI-SceI. The / fold is a hallmark of LAGLI-
DADG proteins and has since allowed for better homology 
modeling and structure/function prediction for proteins lack-
ing structural data. 
  It has been estimated that LAGLIDADG proteins specifi-
cally recognize a DNA sequence ranging from 14 to 40 base 
pairs in length. Although the initial structures were solved in 
the absence of target DNA, several labs were able to success-
fully exploit the structural data to better understand protein-
DNA interactions. First, it was clear from the PI-SceI struc-
ture that the additional splicing domain characteristic of in-
tein-encoded proteins was flanked by a region capable of 
specifically contacting DNA [148, 149], a concept borne out 
when the DNA co-crystal structure was finally solved [150]. 
These studies addressed the co-evolution of the endonuclease 
domain (domain II) with the surrounding splicing domain 
(domain I). Second, having structural data allowed for better 
predictions regarding studies aimed at investigating the de-
terminants of specificity. Whereas it had previously been 
known that most homing endonucleases could tolerate sin-
gle-base changes throughout their recognition sequence, site-
sequence degeneracy studies could be rationalized (I-CreI 
[151], PI-SceI: [152]). Nevertheless, it was only a short time 
later that DNA co-crystal structures were available, giving 
not only the first glimpse of LAGLIDADG protein-DNA 
contacts (I-CreI [153]) but also enabling theories about the 
nature of catalysis [154, 155]. Despite each subsequent co-
crystal structure adding individual idiosyncrasies to the over-
all picture of LAGLIDADG protein-DNA interactions [150, 
155-162], several generalities persist: (i) specificity contacts 
arise from the burial of the extended -strands into the major 
groove of the DNA, with the DNA binding saddle having a 
pitch and contour mimicking the helical twist of the DNA; 
(ii) although extensive, the complete complement of hydro-
gen bonding potential between the protein and DNA is never 
fully realized, with many contacts being water-mediated; (iii) 
cleavage to generate the characteristic 4-nt 3’-OH overhangs 
occurs across the minor groove, wherein the scissile phos-
phate bonds are brought closer to the protein catalytic core 
by a distortion of the DNA in the central “4-base” region; 
(iv) cleavage occurs via a proposed two-metal mechanism, 
sometimes involving a unique “metal sharing” paradigm; (v) 
and finally, additional affinity and/or specificity contacts can 
arise from “adapted” scaffolds, in regions outside the core 
/ fold. 
  On first inspection it appears that these generalities could 
define a fixed rule-set, which could help manipulating LA-
GLIDADG protein-DNA interactions. However, several 
studies have shown that related proteins can use different 
subsets of residues to recognize similar DNA [158, 163]. As 
discussed below, this “relaxed” property of meganucleases 
has proved to be a double-edge sword, making it at once 
both easy and problematical to re-engineer specificity. 
Engineering Meganucleases 
  The meganuclease field has recently exploded with novel 
and interesting engineering applications. In a “bulk ap-
proach”, several teams tested the concept of subunit inter-
changeability by fusing both similar and disparate / do-
mains, giving rise to hybrid proteins having hybrid specific-
ity derived from each half of the parental protein targets 
[157, 164, 165]. These proof-of-concept studies addressed 
not only the feasibility of a “mix and match” approach but 
also the evolutionary concept that double-motif LAGLI-
DADG proteins arose from a gene duplication event. Gene 
fusion alleviates the restriction imposed by homodimers to 
symmetric or pseudo-symmetric targets by allowing for 
asymmetric mutations in each subunit and thus recognition 
of asymmetric DNA targets. This model has undeniably 
proved valuable in paving the way for selection and screen-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Proposed life-cycle of a homing endonuclease (see text for details). Adapted from [145]. 
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ing studies based on the independence of DNA recognition 
by individual / subunits. 
  Several strategies for engineering meganucleases involve 
a semi-rational approach in which specific residues are mu-
tated on the basis of prior structural or functional knowledge 
to create libraries with limited diversity. Using I-CreI as a 
model scaffold, several groups have been able to alter its 
DNA recognition properties both on a small and large scale 
in terms of total proteins re-engineered. Initial successes with 
the I-CreI [166-168] and I-SceI scaffolds [169, 170] resulted 
in the identification of only a few mutants due to the limited 
screening technologies. To analyze a much larger number of 
mutant/target combinations, an automated high-throughput 
screening method was used for the I-CreI scaffold, resulting 
in the identification of hundreds of mutants with locally al-
tered specificities [171, 172]. These variants were shown to 
maintain the essential properties of the initial scaffold, i.e. 
proper folding and stability, cleavage efficiency and a nar-
row specificity. This has since led to a combinatorial ap-
proach in which different sets of I-CreI mutants are com-
bined in the same protein, resulting in entirely redesigned 
meganucleases cleaving chosen sequences [172, 173]. 
  Currently, engineered meganucleases cleaving two dif-
ferent human genes, XPC and RAG1 [172, 173], as well as a 
meganuclease cleaving a maize genomic sequence [142], 
have been described in the literature. Additionally, continued 
engineering efforts have allowed the production of custom 
meganucleases cleaving several dozens of chosen natural 
sequences (our unpublished data). While on the surface these 
studies solidify the practicability of altering meganucleases, 
bona fide engineering of specificity has proved to be more 
complex. Progress remains to be made if one wants to use 
the full potential of other LAGLIDADG proteins, including 
natural single-chain variants. Detailed studies of the LA-
GLIDADG scaffold have demonstrated noteworthy pitfalls, 
including differences in how each subunit interacts with 
DNA, either in a homodimer context to efficiently bind 
asymmetric DNA [162] or within the same monomer, dis-
playing a disparity in affinity vs. specificity [174]. Moreover, 
regions outside the core fold have been implicated in being 
important for target site DNA interactions [175]. Finally, the 
homodimer nature of the proteins themselves creates an in-
herent impasse when designing proteins for asymmetric tar-
gets, as three species of functional enzyme will arise in the 
mix. 
  Fortunately, the future of meganuclease engineering is 
quite promising as all of these challenges are being over-
come and in the process innovative studies have shed light 
on new and exciting avenues. Comprehensive computational 
studies have given rise to not only specificity re-engineering 
[176], but have also addressed the dimerization issue via 
targeting protein-protein interactions of the subunits [177] as 
well as through mimicking nature with single-chain designs 
[178, 179]. Exhaustive analysis of the I-AniI scaffold [180, 
181] has led to better computational methods that can exploit 
binding energy for designs [180]. Through both computa-
tional [182] and structural [161] analysis of novel structures 
of engineered proteins in complex with DNA, insight has 
been gained into the intricacies of the protein-DNA contacts 
that appear to involve substantial conformational changes in 
both the protein and/or DNA; findings that suggest specific-
ity engineering is more than a point-by-point process Fig. 
(2). Moreover, new opportunities are being explored through 
the generation of targeted “mega-nickases” (I-SceI [183], I-
AniI [184]) that can in principle provide similar levels of 
induced HR with a minimization in the frequency of NHEJ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Re-engineering meganuclease specificity: example of a custom meganuclease targeting a sequence from the human XPC gene. (a) 
Comparison of the starting and final targets. (b) Crystal structure of the engineered I-CreI variant in complex with target DNA. Details of 
protein-DNA contacts from the encircled region are highlighted (c) to demonstrate how a clustered approach leads to significant changes in 
specificity contacts. The native protein-DNA contacts for I-CreI (d) are shown for reference. Adapted from [161]. 
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Use of Meganucleases for Genome Engineering 
  DNA damage is a naturally occurring event that can lead 
to chromosomal aberrations or cell death. DSBs are particu-
larly hazardous to the cell as they can potentially lead to ge-
nome rearrangements. Not surprisingly, a variety of repair 
strategies have evolved to ensure genomic integrity. As out-
lined above, these processes can be either error-prone 
(NHEJ) or conservative (HR), depending on the mechanisms 
involved. Understanding the nature of each mechanism can 
be crucial in the context of gene targeting. Namely, from the 
genome engineering point of view, the challenge of using the 
cellular DNA repair machinery lies in creating a precise DSB 
in a genome. 
  I-SceI is the prototypical meganuclease used for genome 
engineering. In nature, the protein stimulates HR by creating 
a site-specific DSB in the genome, in a process called hom-
ing (see above). The discovery of this function in the yeast 
Sacharomyces cerevisiae launched a new era in gene target-
ing [185]. Researchers studying DNA repair in mammalian 
cells soon realized the potential of such a tool. In the nine-
ties, pioneering work used a chromosomal neomycin resis-
tant gene interrupted by an I-SceI recognition site as a re-
porter to monitor gene correction events in mouse cell lines 
upon introduction of an I-SceI expression vector and a DNA 
repair matrix. Gene correction could be achieved at frequen-
cies of 3x10
-5 in ES [186] and 4x10
-4 in NIH3T3 [187] cells. 
Further experiments in NIH3T3 and PCVC7 cell lines were 
able to show that targeted gene insertion could also be ob-
tained using this approach [188, 189]. In contrast to cell 
populations that received the DNA repair matrix alone, 
where no targeted events could be detected, frequencies of 
1.8x10
-4 to 4x10
-4 targeted events per transfected cell could 
be achieved. Later studies were able to realize an even higher 
frequency of gene targeting. For example, Donoho and col-
leagues obtained nearly 1% recombination in ES cells [190], 
while Szczepek and coworkers could attain up to 10% with 
I-SceI (used as positive control) in 293 cells [191]. These 
analyses paved the way for the DSB-induced gene targeting 
technology, as they demonstrated a >1000-fold stimulation 
of events attributable to the activity of the meganuclease. 
Since then, this simple system has been widely adopted by 
the scientific community and has allowed for a better under-
standing of the DNA repair mechanism in a variety of cell 
types and experimental conditions [89]. 
  Despite the notion that HR precisely repairs the template, 
in certain cases imperfect targeting events were reported, the 
consequences of which would be notable for therapeutic ap-
plications [187] [186]. These results highlighted the neces-
sity to understand the intricacies of HR. For example, it was 
found that HR can occur at one end of the DNA junction 
while non-homologous recombination is carried out at the 
other. In a similar vein, the possibility to correct (or intro-
duce) a point mutation at a distance from the DSB was stud-
ied. It was determined that the double-strand break repair 
(DSBR) pathway can result in the conversion of sequences 
adjacent to the DNA break, wherein the efficiency of the 
conversion decreases as the distance from the DSB increases. 
Elliott and colleagues observed a very sharp decrease of the 
conversion efficiency: a polymorphism located at a distance 
of circa 100 bp from the DSB was corrected in only 13-16% 
of the repair events, and by 400 bp correction dropped to 
only 3%. [192]. Meanwhile, Donoho and coworkers reported 
longer conversion tracts, with up to 13% correction at a dis-
tance of about 4000 bp from the DSB [190]. Finally, experi-
ments in the human cell line 293H have shown that a muta-
tions located 265 bp from the DSB could be efficiently 
(66%) corrected [193]. Despite the apparent discrepancies in 
these results, most likely arising in part from experimental 
design differences, the trend in conversion efficiency ob-
served as a function of distance remains an important point 
to consider for any gene targeting approach. 
  Ultimately, the studies made with the I-SceI system to 
decipher the cellular mechanisms of DSBR have laid the 
foundation for all the main strategies envisioned today for 
genome engineering purposes (Fig. (3)). Gene correction 
[194, 195], gene insertion [189, 190, 196], and gene inactiva-
tion through a NHEJ mechanism [130] as well as the elimi-
nation of a DNA sequence by single-strand annealing (SSA) 
assays between direct repeats [130, 190, 197] were all ad-
dressed during these early studies. This last approach appears 
highly efficient as I-SceI is able to induce recombination 
between direct or inverted repeats at frequencies of up to 10
-1 
events among transfected mammalian cells. A similar fre-
quency was obtained in vivo after tail-vein injection of an 
adenovirus expressing I-SceI into transgenic mice carrying a 
LacZ-based reporter gene: up to 1.3% of the hepatocytes 
showed recombination events [198]. Although cell-line de-
velopment for protein production does not represent the fo-
cus of this review, it is worth mentioning that genes inserted 
by meganuclease-induced recombination show reproducible 
expression levels among targeted cellular clones [199, 200]. 
  The I-SceI-based HR system has also been used to ad-
dress fundamental questions that in many ways also gauge 
the limits of the methodology. For instance, the possibility of 
utilizing the homologous chromosome or an ectopic chromo-
somal locus as a repair template for I-SceI induced DSBR 
was investigated using cultured cells [201, 202]. In terms of 
gene therapy, this strategy would provide a tremendous ad-
vantage in the correction of mutations responsible for domi-
nant monogenetic disease as the introduction into cells of the 
meganuclease could alone lead to gene correction. Unfortu-
nately, when sequences are located on separate homologous 
or heterologous chromosomes, the recombination efficiency 
is extremely low (10
-6-10
-5 events among transfected cells), 
making this approach impractical for therapeutic applica-
tions. Experiments using the template-based method have 
nevertheless shown that, in addition to mammalian cells, I-
SceI-mediated recombination is robust and efficient in di-
verse organisms. It has been successfully used to induce 
various modifications such as mutagenesis, recombination 
between repeats or gene targeting in bacteria [203-207], 
mosquito [208, 209], fly [210] and plant [134, 211-216]. I-
SceI has also been used to improve transgenesis efficiencies 
in various organisms such as frog [217], fly [218], fish [219], 
and sea anemone [220]. 
  An obvious drawback to the use of natural meganucle-
ases lies in the need to first introduce a known cleavage site 
into the region of interest. Although so-called pseudo-sites 
within a genome can be exploited by certain methods (e.g. 
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ble in therapeutic cases where targeting can demand a more 
stringent level of precision. To this end, engineered meganu-
cleases are poised to address the targeting issue and should 
allow for a broader use of HR-based technology. Extensive 
characterization of an engineered I-CreI derivative cleaving 
the human RAG1 gene [178] has indeed demonstrated that a 
fully redesigned meganuclease can compare to I-SceI in 
terms of both efficacy and specificity. This RAG1 endonu-
clease could be used to induce 6% recombination in 293 
cells and its relative specificity was comparable to that of I-
SceI [178]. Similar results (1 to 20% targeted recombination) 
have been obtained in transfection experiments using other 
immortalized cell lines, not only with the RAG1 meganucle-
ase but with many other I-CreI-derived engineered meganu-
cleases tailored to uniquely cleave diverse targets in the hu-
man genome (our unpublished data). 
DIFFERENT STRATEGIES FOR GENE THERAPY 
BASED ON ENDONUCLEASES 
  In this section, the major strategies envisioned for the 
therapeutic use of rare-cutting endonucleases are outlined. 
Gene Correction Approaches 
  Several strategies exist for choosing the nature of the 
meganuclease-induced modification as well as the design of 
the targeting construct. Meganucleases can in principle be 
used to accomplish what may be considered as “ideal” gene 
therapy: true reversion of the deleterious mutation. This ap-
proach has practical limitations, since the efficacy of correc-
tion decreases rapidly as the distance from the initial DNA 
double-strand break increases. As a consequence, this ap-
proach can only be considered in diseases caused by a preva-
lent (and, in theory, targetable) mutation, such as sickle cell 
anemia [221]. An alternative approach along the same lines 
could involve inserting the whole coding sequence upstream 
of a deleterious mutation. In this case, although regions of 
the damaged gene would remain, they would be effectively 
“silenced” by the newly inserted corrected gene. 
  Gene repair strategies can more easily be envisioned 
wherein the particular disease itself presents a selective ad-
vantage upon treatment by gene therapy, such as SCID [222] 
or Wiskott-Aldrich syndrome (WAS) [223] . Endonucleases 
targeting two different genes involved in SCID diseases have 
been described to date: (i) the IL2RG gene that has been 
targeted by a ZFN [104, 105], and; (ii) the RAG1 gene, for 
which a meganuclease has been re-engineered to target [172, 
178]. In vivo, there is a selective advantage for cells with a 
functional gene because signaling through the c cytokine 
receptor or possessing a functional RAG1 recombinase con-
fers a survival and/or proliferation signal during differentia-
tion of lymphocytes [222, 224]. The IL2RG ZFN has been 
used in a variety of immortalized and primary cells. An ini-
tial design was used to achieve gene targeting in 18% of 
treated K562 cells, and 5% of treated T cells [104]. Using the 
latest ZFN variants engineered for minimal toxicity [105], 5-
15% gene insertion has been observed in transfection ex-
periments in K562 cells [109]. The use of non-integrative 
lentiviral vectors resulted in up to 6% of targeted insertion 
[103]. Likewise, with the meganuclease targeting the RAG1 
gene, aiming at the same correction approach, up to 6% of 
targeted modifications could be observed in transfection ex-
periments using 293 cells [178]. For comparison, the RAG1 
meganuclease and the IL2RG ZFN appear to yield the same 
frequencies of homologous gene targeting in 293 cells (our 
unpublished data). In principle, these frequencies should be 
enough for an ex vivo treatement of SCID diseases, provided 
one can achieve them in hematopoietic stem cells (HSCs). 
However, achieving high efficiencies in HSCs might be 
problematic (see below, THE EFFICACY AND SAFETY 
ISSUES), and future studies will tell whether the quality of 
the nucleases reported above will be high enough to com-
pound the intrinsic difficulties linked with the handling of 
human HSCs. 
 
 
 
 
 
 
 
 
Fig. (3). Endonuclease-induced gene targeting approaches. Upon cleavage, DNA repair mechanisms may result in one of several outcomes. 
When a double-strand break is targeted between two direct repeats (a), homologous recombination can result in the deletion of one repeat 
together with the intervening sequence. Gene insertion (b) or correction (c) can be achieved by the introduction of a DNA repair matrix con-
taining sequences homologous to the endogenous sequence surrounding the DNA break. Mutations can be corrected either at or distal to the 
break, with the frequency of correction decreasing with increasing distance. The misrepair of DNA ends by error-prone non-homologous end 
joining (d) can result in insertions or deletions of various sizes, leading to gene inactivation. 
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  Other nucleases have been engineered to target genes 
whose correction by homologous gene targeting could be of 
therapeutic relevance. For example, a recent report describes 
a ZFN targeting the human PIG-A gene, involved in parox-
ysmal nocturnal hemoglobinuria (PNH) [108]. This ZFN 
allowed for gene targeting of 3% of transfected 293 cells, but 
these figures decreased by at least 100 fold in stem cells 
([108]. Two meganucleases targeting the human XPC gene 
have also been described, but these proteins were tested only 
with reporter systems [161, 173], with targeting frequencies 
between 0.1% and 1% (our unpublished data). With these 
frequencies, the use of such nucleases will depend on selec-
tion procedures to sort targeted events. For therapeutic pur-
poses, the selection scheme should be both (a) as non-
invasive as possible, and; (b) at the expense of the multipo-
tency or progenitor capacity of the treated cells. 
Insertion of Therapeutic Genes into a Safe Harbor 
  An increasingly popular approach in gene therapy today 
seems to be the targeted insertion into a so-called “safe har-
bor”. This strategy consists of introducing genetic material 
into a predefined locus unrelated to the disease-causing gene. 
In contrast with true gene correction, targeted insertion is not 
limited to the use of methods based on homologous gene 
targeting, and targeted recombinases or transposases could 
perform as well. 
  For this method to be valid, the locus of interest must 
possess two essential properties. First, an adequate safe-
harbor locus needs to support sufficient and stable gene ex-
pression in the modified cells. For the gene therapy to be 
effective, the inserted element of interest must be available 
in the host at functional, if not “wild-type”, levels. Second, 
and most importantly, the safe-harbor locus needs to be 
“safe” in terms of not interfering with normal cell function 
and gene regulation. Adverse events could be caused by the 
deregulation of other genes, either by repression or induction 
of gene expression, or by inducing chromosomal instability. 
The difficulty in the safe-harbor approach stems from the 
ability to predict that a particular locus is safe, and many 
different strategies are currently being explored. For exam-
ple, a ideal site for transgene expression was identified in 
mouse genetics studies of the ROSA26 locus, where inser-
tion of a coding sequence leads to its constitutive expression 
without altering viability [225]. However, there is no evi-
dence that the homologous human locus is similarly “safe”. 
A promising safe harbor is the AAVS1 locus, the most 
common integration site for AAV, a parvovirus lacking a 
known associated pathology [226]. AAVS1 is located on 
chromosome 19 within intron 1 of the PPP1R12C gene, and 
has been shown to allow inserted exogenous DNA to be 
transcribed [226, 227]. ZFNs targeting AAVS1 have recently 
been developed and used to induce targeted insertions in 
immortalized cell lines and primary cells, with stable expres-
sion of the transgene [107, 228]. In transfection experiments, 
frequencies of targeted events could reach circa 10% in 
K562 cells, 3% in HEK293 and Hep3B cells, and similar 
values in other cell lines. Gene targeting could also be ob-
served in human stem cells, e.g. ES and iPS cells. However, 
targeted events were identified after selection for transfor-
mants having integrated a reporter gene placed in the repair 
matrix. Whereas targeted events represented a large fraction 
of the integrations (up to 61%), it is difficult to infer the ab-
solute rate of gene targeting (e.g. the ratio of targeted events 
per transfected cell) in these studies [107, 228]. Neverthe-
less, on can suspect that it is low, which again raises efficacy 
issue for real-world therapeutic applications. If the use of a 
selection scheme has to be envisioned, it is with caution, for 
it would have to be non invasive and not affect the multipo-
tency of the targeted stem cells. Future studies should tell 
whether the current targeting protocols can avoid selection 
procedures that might prove problematic. 
  While the above examples illustrate active research on 
potential safe-harbors, the choices of loci in these cases were 
fortuitous. However, given the constant progress in genome 
annotation, the mapping and description of multiple features 
(e.g. GC-clusters, non-coding RNA genes, sequence varia-
tions, chromatin-immunoprecipitation, mRNA expression 
pattern, etc) are available from publicly accessible databases, 
allowing for semi-rational selection of safe harbor loci. Per-
haps the simplest way to keep cellular expression profiles 
unaltered is to target loci distal from functional genes, with 
an emphasis on avoiding tumor suppressor genes. While 
basic in concept, this strategy does not fully address the issue 
of effects on chromatin remodeling or chromosomal stabil-
ity. The cell type that needs to be targeted must also be taken 
into account when investigating the usefulness of a particular 
locus. For example, a locus that supports stable gene expres-
sion in hematopoietic stem cells might not provide the same 
expression in neurons or hepatocytes. This discrepancy may 
arise from many factors, one of which being the variability in 
whether a safe locus is indeed “safe” in different cell types. 
In all cases, it must be noted that the choice of a viable safe 
harbor is coupled to its ability to be efficiently targeted, ei-
ther by preexisting or engineered nucleases. Thus, beyond 
the issues of safety and stable gene expression, safe harbor 
accessibility must be considered in light of nuclease target-
ing potential, which could vary along the genome and be-
tween cell types, due to epigenetic modifications (there is at 
least one example in plants of a nuclease targeting two ex-
actly identical sequences with different efficacies, these two 
different sequences being found in two different loci, in the 
SurA and SurB genes [106]). Despite these technical obsta-
cles, the identification of a good safe-harbor/nuclease pair 
appears to be a readily attainable goal. Notably, an additional 
advantage of using a safe harbor strategy is that it can also be 
utilized in multiple indications as different genes can be ex-
pressed from the same locus. 
Targeted Mutagenesis of Human Genes 
  The use of meganucleases to target a mutagenic event at 
a specific locus is actively being investigated for numerous 
purposes. As evidenced by its widespread use in model sys-
tems, targeted mutagenesis can also have therapeutic per-
spectives. The selective disruption to restore the wild-type 
phenotype of mutated alleles in dominant diseases remains a 
challenge: an endonuclease able to discriminate the mutated 
allele from that of the wild-type is required. Whereas the 
treatment of monoallelic diseases by targeted mutagenesis 
represents an interesting concept, more practically this ap-
proach can be applied to the inactivation of unwanted genetic 
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  ZFNs have recently been used to inactivate the CCR5 
gene, a co-receptor for HIV entry, leading to resistance 
against HIV infection [16]. Inactivation of 50% of CCR5 
alleles could be observed in primary human CD4+ cells, 
providing selective advantage to CCR5
-/- double-mutant cells 
upon HIV1 infection in vitro and in an in vivo mouse model. 
Genotoxicity and specificity were assessed by the absence of 
DNA-repair protein foci formation, and by testing the fre-
quency of induced mutagenesis at other potential cleavage 
sites. This work led to the opening in 2009 of a new clinical 
trial for AIDS patients, the first one involving a rare-cutting 
endonuclease. Recently, ZFN could also be used to inacti-
vate CCR5 in human CD34+ cells [229]. These results pro-
vide a first step toward a therapeutic approach with the po-
tential to create HIV resistant cells in all the blood cell linea-
ges, instead of only within the T cell population. 
Virus Clipping 
  Nucleases targeted against viral sequences represent a 
novel class of antiviral agents that could cleave and either 
partially excise or completely eliminate viral DNA from in-
fected cells, rendering them essentially “virus free”. This 
strategy mimics the cleavage of foreign DNA by restriction 
endonucleases in bacteria. The advantage of disrupting the 
viral genome, and not the various steps of viral replication, 
lies in the possibility of targeting latent forms of the virus. 
Latent viruses persist in the cell and are normally not af-
fected by conventional treatments, which are effective only 
when the virus is actively replicating. This approach can be 
envisioned for different types of viruses, given that a double-
strand DNA (dsDNA) stage is part of its lifecycle. Retrovi-
ruses, for example, constitute a large group of RNA viruses 
that upon entry into the target cell will generate by reverse 
transcription a dsDNA molecule that integrates into the host-
cell genome. Other viruses that can be targeted by engi-
neered meganucleases include the Polyomavirus, Papillo-
maviruses, Herpesvirus and Hepadnavirus, all of which be-
long to the group of DNA viruses and for which the genomic 
DNA remains as an episomal molecule in infected cells. Po-
tential mechanisms are outlined in Fig. (4). 
  The feasibility of virus clipping is in the process of being 
validated by recent examples in the literature. For instance, it 
has been shown that ZFNs targeting Hepatitis B virus (HBV) 
DNA can efficiently cleave an HBV sequence present within 
a plasmid transfected in cultured cells [230]. Analysis of the 
DNA target reveals misrepair of affected HBV sequences 
within cultured cells coupled with a drop in pre-genomic 
viral RNA levels, an indicator of replication competence in 
cellular models that mimic HBV infection. Another promis-
ing approach lies in the prevention of viral infection using 
targeted meganucleases. Using a recombinant Herpes sim-
plex virus (HSV-1) harboring an I-SceI restriction site, it was 
demonstrated that viral replication is impeded in COS-7 cells 
that have been transfected with a plasmid coding for the I-
SceI meganuclease prior to infection (Smith et al. 2010, 
submitted). Furthermore, redesigned meganucleases derived 
from I-CreI were generated that are able to recognize and 
cleave sequences from the HSV genome. These HSV-
specific meganucleases, when transfected prior to infection 
with a wild-type strain of HSV-1, reduce the levels of viral 
genomic DNA more than 50% compared to cells transfected 
with an empty vector. Still, while the above examples of 
virus clipping appear successful, efficacy remains to be as-
sessed for integrated viral forms. Early experiments suggest 
that cleavage in both LTRs could result in viral genome loss, 
by tandem repeat recombination or rejoining of the two 
DSBs [130, 188, 197]. How these issues will be addressed 
remains to be seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Meganucleases as antiviral agents. Pathways by which 
viral sequences belonging either to essential genes or regulatory 
regions can be inactivated are shown. Gene inactivation can result 
from small insertions/deletions that introduce lethal mutations in 
the viral genome by error-prone non-homologous recombination 
(panel a). Large deletions can be introduced by DNA cleavage and 
repair when using two different meganucleases targeting the same 
viral genome at different positions (panel b), or by rejoining DNA 
ends when cleavage occurs in a repeated region of the viral genome 
(panel c). Alternatively, when cleavage occurs between two direct 
repeats (e.g.: the LTR retroviral sequences), deletion of the inter-
vening sequences can be generated by tandem repeat recombination 
(SSA, panels a and b). While the pathways depicted in panels a-c 
are valid for integrated as well as episomal viruses, the latter can 
also be targeted via the degradation and clearance of the viral ge-
nome upon DNA cleavage (panel d). 
THE EFFICACY AND SAFETY ISSUES 
  In 2005, Urnov and colleagues created an engineered 
ZFN targeting the human IL2RG gene. By early 2010, a 
handful of diverse engineered nucleases able to edit human 
genes with high efficiency were described in the literature 
[16, 103, 105-108, 111, 178, 228]. One of these, a ZFN that 
can induce gene knock-out by NHEJ, is even in clinical trial 
[16]. These data reflect both the potential and limits of the 
technology as applied today.  
Frequencies of Targeted Genome Modifications 
  In reviewing the different alternatives to viral gene trans-
fer for gene therapy, it becomes clear that multiple factors 
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can influence the success of each given approach. All tar-
geted methods have aimed at reaching a symbolic “1% ratio” 
of targeted integration. Nevertheless, subtle variations such 
as reagents used, cell-types targeted, vector construction and 
even data analysis methods can have a significant impact on 
reported frequencies. Nucleases-based methods as discussed 
herein can achieve frequencies of >5% in immortalized cells, 
clearly indicative of the potential these approaches hold. 
However, a few recent studies suggest that these figures can 
strongly decrease in stem cells, which might represent one of 
the major hurdles for such technologies. 
  Lombardo and co-workers used a ZFN cleaving the hu-
man CCR5 gene to induce targeted insertion in different cell 
types [103]. Using non-integrative lentiviral vectors instead 
of transfection, up to 50% of targeted events were observed 
in K562 and Jurkat cells, about 5% in ES cells, and close to 
0.1% in CD34+ cord blood progenitor cells [103]. However, 
Zou and colleagues observed lower figures in human ES 
cells [108]. Using ZFNs targeting a GFP reporter gene, they 
obtained frequencies in the range of 3% in 293T cells, but 
only of 0.1-0.2% in hES and iPS. With a tailored ZFN target-
ing the PIG-A human gene, the same authors observed even 
lower frequencies, in the range of 2-4x10
-4 for human ES 
cells, and 10
-5 for human iPS. In another study, Hockemeyer 
et al. used a selection process to identify targeted recombina-
tion events induced by tailored ZFNs in the human OCT4, 
AAVS1 and PITX3 endogenous genes in human ES and iPS 
cells. High frequencies of targeted integrations were ob-
served among transformants (up to 61%), but the absolute 
rate of gene targeting is not indicated [107]. 
  Discrepancies between the studies of Lombardo and col-
leagues and those of Zou and coworkers in the observed tar-
geted recombination frequencies in hESCs could be due to 
the methods used, the quality of the nuclease employed, or 
even the cell type. In any case, efficacies in stem cells seem 
to be far below what can be achieved with viral vectors, or 
even non-viral methods such as those utilizing enhanced 
versions of the Sleeping Beauty transposon [70]. 
  One hypothesis to explain the low frequencies of HGT 
events observed by Lombardo et al. in CD34+ cells, and by 
Zou  et al. in human ES and iPS cells, is that these cells 
would be less proficient for HR. In principle, endonuclease-
mediated mutagenesis should be less limiting than HR-based 
approaches, for NHEJ is not limited to the S/G2 phases of 
the cell cycle. Nevertheless, lower efficacies can result from 
factors other than a limiting repair pathway. The induction of 
indels by endonucleases has been reported for several cell 
types and organisms, often with impressive efficacies: the 
CCR5 gene could be mutated with frequencies in the range 
of 30-54% in primary T-cells using an adenoviral vector 
expressing a ZFN [16]. Zou et al. also monitored the fre-
quency of targeted mutagenesis induced by their PIG-A 
ZFN, and observed only 4.6x10
-6 of indels in ES cells. This 
frequency, about 100 times lower than the frequency of 
DSB-induced HGT in the same cells, has to be considered 
cautiously, for it was monitored by a selection process. 
However, it suggests that the limiting factor in hES cells 
could actually be suboptimal vectorization and/or lower ex-
pression levels of the endonuclease, which would affect both 
HGT and targeted mutagenesis. 
  These data emphasize the need for a more complete body 
of data regarding targeted recombination in stem cells, and 
likely reflect the inherent difficulties in handling these cells, 
regardless of the mechanism of action (targeted mutagenesis 
or HGT) of the nuclease. 
Specificity 
  Whereas the efficacy of targeted approaches can be 
measured in terms of directed events (e.g. percent mutagene-
sis at the targeted locus), a true benchmark for specificity 
remains elusive as the very nature of monitored events can 
vary by assay. For instance, the detection of repair protein 
foci (phosphorylated H2AX or 53BP1) is routinely used to 
measure nuclease toxicity [16, 105, 178, 191, 231, 232]. The 
high levels of repair foci that occur naturally in immortalized 
cells, however, make this assay relatively insensitive despite 
the assayed proteins being highly specific. A more straight-
forward assay using immortalized cells involves monitoring 
cell survival in the presence of increasing doses of nuclease 
to compare the relative toxicity of different endonucleases 
[106, 178, 232, 233]. This assay in turn suffers from being 
hardly predictive of what will happen in true target cells, 
wherein expression will likely be more limited. Endonucle-
ase-induced indels have also been a major concern and sev-
eral studies have described the characterization of mutagene-
sis in promiscuous sequences, typically found to be null or 
infrequent [16, 107]. However, targeting the CCR5 gene 
with a dedicated ZFN induced significant mutagenesis in the 
related CCR2 gene (4-5% for CCR2 versus 36% for CCR5) 
[16] . Furthermore, studies showing that the occurrence of 
several DSBs can result in translocation have raised addi-
tional concerns [234, 235]. The toolbox for characterizing 
potential genotoxicity certainly needs to be upgraded to ad-
dress these issues, and several efforts are currently under-
way. 
  A number of standard quality control tests can be used to 
test the status of stem cells, e.g. monitoring (i) growth rate; 
(ii) karyotype; (iii) cell morphology; (iv) the expression of 
genes marking the differentiation status, and; (v) multipo-
tency (differentiation tests in vitro or in vivo). Such tests 
have been used after stem cell engineering with nucleases 
[107, 108], but also with other reagents [70], without detec-
tion of any gross alteration. Finally, using a humanized 
mouse model to study the fate of engineered cells [16] ap-
pears effective for assessing both activity and safety. 
CONCLUSION 
  The difficulties in harnessing the potential of endonucle-
ase-based targeted approaches can best be placed in perspec-
tive when one considers that the first clinical trial using these 
methods involves a gene knock-out technique. The purpose 
of replacing current methods that use random transgene in-
sertion by those using targeted recombination is to have bet-
ter control over the resulting engineered cells. More specifi-
cally, the goal is not only to promote and dictate transgene 
expression, but also to avoid adverse events such as inser-
tional mutagenesis. In addition, these benefits need to be 
significant. For example, whereas retroviral gene transfer in 
20 patients treated for X-SCID [3, 5] and 2 patients treated 
for CGD [6] resulted in several cases of leukemia (X-SCID) 22    Current Gene Therapy, 2011, Vol. 11, No. 1  Silva et al. 
or myoplasia (CGD), hundreds of patients have received T-
cells engineered with similar vectors [236] without a single 
occurrence of induced malignant transformation. In these 
cases the integration sites were different from those com-
monly found in HSCs, perhaps explaining the absence of 
SAEs [237]. Thus, safety concerns can vary depending on 
the indication. 
  The benefits of targeted methods must also not be at the 
expense of new or unexpected significant drawbacks. In the 
case of endonuclease-mediated recombination, the obvious 
potential drawbacks are (i) a potential genotoxicity that re-
mains to be assessed, and; (ii) lower efficacy. Genotoxicity is 
an inherent problem of enzymes that act on nucleic acids, 
though one can expect that highly specific endonucleases 
would reduce or abolish this issue. The lower efficacy, on 
the other hand, stems from limitations in the levels of ho-
mologous recombination within the cells, an obstacle under-
scored by experiments in stem cells and especially in HSCs. 
Several studies aspire to alleviate this tissue-specific vari-
ability by using iPS cells, although it not clear if (a) they 
display better recombination rates or; (b) they will be accept-
able for cell therapy in the short term. 
  Currently, random insertion using a quality vector (pref-
erentially a viral one) is more efficient than the highest re-
ported targeted-insertion rate, regardless of the cell type. For 
any emerging method it is therefore important to strive for 
both an excellent recombination rate as well as a low thresh-
old in terms of required activity. Whereas the activity level 
depends on the cell type (for HR proficiency) and vectoriza-
tion (to bring enough nuclease and repair matrix into the 
target cell), the threshold of required activity rather depends 
on the indication. The real question is whether the efficacies 
described above represent a limit. Differences in efficacy 
could be less stringent for indications such as haemophilia, 
wherein expression of 1% of wild-type levels is sufficient to 
result in a therapeutic effect [238]. If gene correction is asso-
ciated with a selective advantage (e.g. SCID diseases), a low 
frequency of repair should be enough to provide a therapeu-
tic effect [89]. Then again, SCID has to be addressed in early 
progenitor cells, which could prove especially difficult to 
target. Whether these limitations also apply to the same ex-
tent for gene knock-out based strategies is unclear. Although 
the CCR5 clinical trial cannot provide a benchmark for 
strategies based on targeted insertion, the absence of toxicity 
reported so far is an important clue for nuclease-based ap-
proaches. Pioneering studies using a good safe har-
bor/nuclease coupled with one of the more “accessible” dis-
eases (such as the ones quoted above) could represent an 
essential milestone, answering many important questions. In 
this respect, the choice of a good nuclease (high activ-
ity/toxicity ratio) targeting a good safe-harbor locus (stable 
expression and no impact on neighboring genes) will be ex-
tremely important. However, the choice of the target cell 
might be at least as important as the mechanism of action of 
the nuclease: recent publications have shown that the use of 
stem cells is associated with potential additional difficulties, 
and it should be noted that the current CCR5 clinical trial is 
based on the treatment of T cells, and not of HSCs (the pos-
sibility to treat HSCs is being currently investigated [229]). 
Furthermore, one can expect that a humanized mouse model 
will be key in deciding whether currently achievable recom-
bination rates in stem cells will be sufficient. 
  For endonuclease-based approaches, proper expression of 
the nuclease within the target cell is certainly one of the most 
important aspects for both efficacy and specificity. A good 
efficacy relies on the introduction of a sufficient amount of 
nuclease into the target cell. Although the off-site cleavage 
of these molecules has been significantly reduced by a vari-
ety of strategies, a low level of activity over an extended 
period of time could have significant consequences. Several 
methods of vectorization have been used for the generation 
of nuclease mediated modification events in human cells, 
including non viral methods (electroporation) and the use of 
viral vectors (AAV vectors, integration-defective lentiviral 
vectors (IDLV) and adenovirus vectors, the latter solution 
being used in the CCR5 clinical trial). Nevertheless, one of 
the biggest advantages of nuclease-based approaches could 
be that they could alleviate the need for viral vectors, which 
represent a real hurdle in terms of GMP manufacturing. In 
this regard, nuclease-based strategies are  more in competi-
tion with transposon-based (targeted or non-targeted) rather 
than with viral vector-based approaches. 
ABBREVIATIONS 
AAV = Adeno-Associated  Virus 
DSB =  Double-Strand  Break 
ES  =  Embryonic Stem (cells) 
HGT  =  Homologous Gene Targeting 
HR =  Homologous  Recombination 
HSC =  Haematopoietic  Stem  Cell 
iPS  =  Induced Pluripotent Stem (cells) 
NHEJ  =  Non-homologous End Joining 
SCID  =  Severe Combined Immune Deficiency 
SFHR  =  Short Fragment Homologous Replacement 
TALE  =  Transcription Activator-Like Effector 
TFO =  Triplex-Forming  Oligonucleotides 
ZFP =  Zinc-Finger  Protein 
ZFN =  Zinc-Finger  Nuclease 
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